FDA PDUFA Target Date for Vertex’s Povetacicept in IgA Nephropathy – November 30 2026

Vertex Pharmaceuticals has submitted a Biologics License Application (BLA) for povetacicept – an investigational therapy for adults with IgA nephropathy (IgAN). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for this application.

Confirmed PDUFA target action date

• Date: November 30, 2026
• Agency action: The FDA will issue a decision on the BLA – which could be an approval, a denial, or an extension of the review period.

The PDUFA calendar published by Biopharma Transcript lists this exact target date for Vertex’s povetacicept BLASource.

Possible outcomes

According to the resolution rules attached to the OdinSignal card, the FDA’s decision may be one of three:

1. Accelerated approval of povetacicept for IgA nephropathy.
2. Rejection of the application.
3. Extension of the review timeline beyond the November 30 2026 deadline.

Uncertainty and what to watch

• The PDUFA date is a target rather than a guarantee of approval. The FDA may request additional data or issue a Complete Response Letter, which would push the decision past the target date.
• No public information beyond the calendar entry confirms the likelihood of any specific outcome.
• Future FDA communications (e.g., press releases, advisory committee meetings) should be monitored for updates on the review status.

Sources

• Biopharma Transcript – PDUFA calendar 2026‑2027, entry for Vertex Pharmaceuticals povetacicept, November 30 2026 target action dateSource.

---

This article presents only the verified schedule and the range of possible regulatory outcomes. It does not predict the result of the FDA review.